Immune Pharmaceuticals Announces 2017 Financial Results

Immune Pharmaceuticals (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the year and quarter ended December 31, 2017.

As quoted in the press release:

Elliot Maza, President and CEO of Immune, commented, “We made notable progress over the course of 2017. We worked diligently to focus our efforts and establish a clear path forward for bertilimumab and NanoCyclo by implementing our strategic corporate restructuring, prioritizing and segregating our research and development efforts, and strengthening our financial position. We have an excellent team in place to support our two exciting programs and advance the Company, and we are well positioned to have a breakthrough year in 2018. We are grateful to our shareholders for their support and look forward to achieving the milestones ahead of us this year.”

Click here to read the full press release.